Novo Nordisk A/S (NVO)
NYSE: NVO · Real-Time Price · USD
49.61
-0.71 (-1.41%)
At close: Jul 20, 2026, 4:00 PM EDT
49.68
+0.07 (0.14%)
After-hours: Jul 20, 2026, 4:58 PM EDT
Novo Nordisk Revenue
Novo Nordisk had revenue of 96.82B DKK in the quarter ending March 31, 2026, with 23.99% growth. This brings the company's revenue in the last twelve months to 327.80B, up 8.13% year-over-year. In the year 2025, Novo Nordisk had annual revenue of 309.06B with 6.43% growth.
Revenue (ttm)
327.80B DKK
Revenue Growth
+8.13%
P/S Ratio
4.38
Revenue / Employee
4,716,207 DKK
Employees
69,505
Market Cap
221.55B USD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 309.06B | 18.66B | 6.43% |
| Dec 31, 2024 | 290.40B | 58.14B | 25.03% |
| Dec 31, 2023 | 232.26B | 55.31B | 31.26% |
| Dec 31, 2022 | 176.95B | 36.15B | 25.68% |
| Dec 31, 2021 | 140.80B | 13.85B | 10.91% |
| Dec 31, 2020 | 126.95B | 4.93B | 4.04% |
| Dec 31, 2019 | 122.02B | 10.19B | 9.11% |
| Dec 31, 2018 | 111.83B | 135.00M | 0.12% |
| Dec 31, 2017 | 111.70B | -84.00M | -0.08% |
| Dec 31, 2016 | 111.78B | 3.85B | 3.57% |
| Dec 31, 2015 | 107.93B | 19.12B | 21.53% |
| Dec 31, 2014 | 88.81B | 5.23B | 6.26% |
| Dec 31, 2013 | 83.57B | 5.55B | 7.11% |
| Dec 31, 2012 | 78.03B | 11.68B | 17.60% |
| Dec 31, 2011 | 66.35B | 5.57B | 9.16% |
| Dec 31, 2010 | 60.78B | 9.70B | 18.99% |
| Dec 31, 2009 | 51.08B | 5.53B | 12.13% |
| Dec 31, 2008 | 45.55B | 3.72B | 8.90% |
| Dec 31, 2007 | 41.83B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Johnson & Johnson | 97.93B |
| Merck & Co. | 65.77B |
| Pfizer | 63.32B |
| AbbVie | 62.82B |
| AstraZeneca | 60.44B |
| Novartis AG | 56.58B |
| Sanofi | 54.60B |
| Bristol-Myers Squibb Company | 48.48B |
NVO News
- 3 hours ago - Novo Nordisk price target raised to DKK 330 from DKK 290 at Citi - TheFly
- 2 days ago - Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics Just Started Testing a Weight Loss Drug That Goes Beyond GLP-1 - The Motley Fool
- 3 days ago - Wegovy Pill Just Changed the GLP-1 Market. Here's Why Eli Lilly Stock Could Still Win - The Motley Fool
- 3 days ago - Novo Nordisk to launch lower-cost Ozempic copy in South Africa - Reuters
- 3 days ago - India approves Novo Nordisk's obesity drug Wegovy for fatty liver disease - Reuters
- 4 days ago - The Next Wave Of Peptides Could Be Here; What Does It Mean For Lilly, Novo? - Investor's Business Daily
- 4 days ago - Novo Nordisk Wins European Commission Nod For Wegovy Pill In Adult Obesity /Overweight - Nasdaq
- 4 days ago - Novo Nordisk AS (NVO) Shares Surge 3.0% -- What GF Score of 76 Tells Investors - GuruFocus